Z
ZENAS BIOPHARMA, INC. COMMON STOCK
NASDAQ: ZBIO (Zenas BioPharma, Inc.)
最近更新时间: 1小时之前31.65
-0.64 (-1.98%)
| 前收盘价格 | 32.29 |
| 收盘价格 | 32.40 |
| 成交量 | 480,995 |
| 平均成交量 (3个月) | 849,941 |
| 市值 | 2,062,843,264 |
| 价格/销量 (P/S) | 1.73 |
| 股市价格/股市净资产 (P/B) | 8.53 |
| 52周波幅 | |
| 利润日期 | 12 Nov 2026 |
| 营业利益率 (TTM) | -373.30% |
| 稀释每股收益 (EPS TTM) | -3.89 |
| 总债务/股东权益 (D/E MRQ) | 0.43% |
| 流动比率 (MRQ) | 6.47 |
| 营业现金流 (OCF TTM) | -137.62 M |
| 杠杆自由现金流 (LFCF TTM) | -77.73 M |
| 资产报酬率 (ROA TTM) | -56.70% |
| 股东权益报酬率 (ROE TTM) | -115.47% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Zenas BioPharma, Inc. | 混合的 | 看涨 |
AIStockmoo 评分
0.5
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | 2.0 |
| 技术平均移动指标 | -1.0 |
| 技术振荡指标 | 0.5 |
| 平均 | 0.50 |
|
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 21.20% |
| 机构持股比例 | 74.88% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Nvp Associates, Llc | 30 Jun 2026 | 1,838,482 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合